Combination Chemotherapy With Cis-Platinum and Ifosfamide for Hormone Unresponsive Prostate Cancer

Maki, Yuho; Tsushima, Tomoyasu; Nasu, Yasutomo; Kumon, Hiromi; Ohmori, Hitoshi; Tanahashi, T; Nanba, Katsuichi; Ohashi, Takuma; Kondo, Katsuyoshi; Sakaguchi, Takashi; Asahi, Toshihiko; Saegusa, Michihisa; Ozaki, Yujiro; Yamashita, Yoshitaka; Katayama, Yasuhiro; Kobuke, Makoto; Uno, Satoshi; Ochi, Junzo; Kobashi, K; Hata, Kenichiro

doi:10.5980/jpnjurol1989.89.657

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although myelosuppression was moderate to severe, no CT-related deaths or sepsis occurred, nor was there any clinical cardiotoxicity. In another study, performed by Maki et al [50], cisplatin/ifosfamide combination therapy was found to be an active regimen in patients with HRPC. Second-generation analogs of cisplatin have been produced which, in early studies, have had quantitatively less toxicity than the parent compound while retaining antitumor activity.…”

Section: Platinum Compoundsmentioning

confidence: 99%

Role of Chemotherapy in Hormone-Refractory Prostate Cancer

Autorino¹,

Lorenzo

Damiano³

et al. 2003

Urol Int

View full text Add to dashboard Cite

Prostate cancer that grows despite castrate levels of testosterone and that no longer responds to any form of hormonal manipulation and for which nonhormonal approaches are required, can be precisely defined as hormone-refractory prostate cancer (HRPC). Until recently, there has been no standard chemotherapeutic approach for HRPC. In this article recent advances in the treatment of HRPC using chemotherapeutic regimens are critically reviewed. We performed a MEDLINE search of the published reports from 1995 to 2002 including chemotherapy in the treatment of HRPC. We critically reviewed a total of 84 clinical trials, of which only 6 were phase III trials, most of the studies being phase II trials. Various chemotherapeutic agents have been used. To date, the major benefits of chemotherapy in the treatment of HRPC are palliative in nature, in terms of reduction of pain and use of analgesics and improvement of performance status, as followed in the most recent trials. There is a promising activity of new drug combinations, such as vinca alkaloids and taxanes in association with estramustine. Mitoxantrone, although with a limited activity, has been shown to provide improvement in pain and quality of life for the patients. Several studies suffer from methodological deficits, such as small number of patients, heterogeneity of enrolled groups or no definitive response criteria. Further phase III studies are necessary to better evaluate the efficacy of the different regimens.

show abstract

Section: Platinum Compoundsmentioning

confidence: 99%

Role of Chemotherapy in Hormone-Refractory Prostate Cancer

Autorino¹,

Lorenzo

Damiano³

et al. 2003

Urol Int

View full text Add to dashboard Cite

show abstract

“…In phase II trials, available cytotoxic drugs (e.g., alkylating agents, anthracyclines, antimetabolites, microtubular inhibitors and Pt-complexes) showed only moderate effects on the hormone refractory PC, with response rates between 27 and 41% (Raghavan et al 1997;Murphy 1999). The combinations of these drugs proved to be more active than their single components, but an extension of the survival time remains to be demonstrated (Maki et al 1998;Huan et al 1999;Gilligan and Kantoff 2002). Recently, attention was drawn to the benefit of satraplatin , an orally administrable Pt-complex, in the treatment of hormone refractory PC (Sternberg 2003).…”

mentioning

confidence: 99%

Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studies

Schertl

Hartmann

Batzl‐Hartmann

et al. 2006

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

[Meso-1,2-bis(2,6-dihalo-3/4-hydroxyphenyl)ethylenediamine]platinum(II) complexes (meso-1-PtLL': 2,6-F(2),3-OH; meso-2-PtLL': 2,6-F(2),4-OH; meso-3-PtLL': 2,6-Cl(2),3-OH; meso-4-PtLL': 2,6-Cl(2),4-OH; L = OH(2), L' = OSO(3) or L,L' = Cl(2)) were designed with the aim to get drugs comprising both cytotoxic and testosterone level lowering potencies. It is assumed that such compounds are more efficient than the established endocrine therapeutic measures and can affect the development of hormone refractory prostate cancer (PC). With exception of meso-3-PtLL' all Pt-complexes and the comparison compound cisplatin significantly reduced the testosterone level in experiments on male rats. However, in the test on the Dunning R3327 PC of the rat only cisplatin and meso-4-PtLL' showed a significant anti-tumor activity at well-tolerated dose ranges. Meso-4-PtLL' also significantly extended the time to disease progression in comparison with orchiectomy in this tumor model. Interestingly, the relapsed tumor, too, responded to meso-4-PtLL' as demonstrated in a long-term study on orchiectomized rats bearing Dunning R3327 PC grafts. This effect cannot be ascribed to cytotoxic effects of meso-4-PtLL' because of its inactivity on the human LNCaP/FGC PC cell line. Therefore, the contribution of an additional mechanism to the anti-prostate cancer activity of meso-4-PtLL', presumably owing to its estrogenic potency, must be considered. This assumption was supported by test results with diethylstilbestrol (DES) (non-steroidal estrogen) on the Dunning R3327 PC of the rat relapsed after orchiectomy. This tumor model was strongly inhibited by DES. The possible mode of action of meso-4-PtLL' is thoroughly discussed.

show abstract

Improvement in urinary retention due to recurrent anastomotic prostate cancer treated with various therapies by intra-arterial infusion of cisplatin and ifosfamide

Uemura

Nishihara

Hayashi

et al. 2012

Journal of Infection and Chemotherapy

View full text Add to dashboard Cite

Although many treatments have been applied to treat hormone-refractory prostate cancer (HRPC), therapeutic outcome is not altogether satisfactory. In the case of locally recurring HRPC, uncontrolled gross hematuria, dysuria, and scalding are often experienced. We report a patient who improved following intra-arterial infusion of cisplatin (CDDP) and ifosfamide (IFM) to treat urinary retention caused by locally recurring HRPC. After chemotherapy, cancer volume was remarkably reduced and symptoms improved.

show abstract

Combination Chemotherapy With Cis-Platinum and Ifosfamide for Hormone Unresponsive Prostate Cancer

Abstract: We conclude that CDDP and IFM combination chemotherapy was active regimen for hormone unresponsive prostate cancer.

Cited by 3 publications

References 0 publications

Role of Chemotherapy in Hormone-Refractory Prostate Cancer

Role of Chemotherapy in Hormone-Refractory Prostate Cancer

Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studies

Improvement in urinary retention due to recurrent anastomotic prostate cancer treated with various therapies by intra-arterial infusion of cisplatin and ifosfamide

Contact Info

Product

Resources

About